ArticleJournal of experimental & clinical cancer research : CR2025

Targeting CXCL8 signaling sensitizes HNSCC to anlotinib by reducing tumor-associated macrophage-derived CLU.

Xin Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.